Major cash injection for Alphabet and AbbVie's R&D program

28 July 2021
abbvie_big

For the second time since its initiation in 2014, a research partnership between AbbVie (NYSE: ABBV) and Calico Life Sciences has been extended, bringing the total investment to over $3 billion.

California’s Calico is a life sciences company run by Google parent Alphabet, founded with the aim of using advanced technologies to increase our understanding of the biology of aging.

The companies are working to discover, develop and bring to market new therapies for patients with age-related diseases, including neurodegeneration and cancer.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Today's issue

Company Spotlight





More Features in Biotechnology